drugset / Trial / NCT00249002
Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis
NaSingle-groupOpen-labelPrevention
Summary
This study is designed to confirm the safety of the proposed dose and schedule of ABI-007 for hemodialysis patients with vascular access device failure, and to obtain preliminary data on the effectiveness of such treatment.
Timeline
- Start
- 2005-11-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
Outcome
Outcome not reported
Stopped: “Terminated due to pipeline prioritization”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABI-007 | Unknown | 35 mg/m2 | Intravenous |
Indications
No indication recorded.